Commodore Capital’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $94.1M | Buy |
4,692,809
+17,809
| +0.4% | +$357K | 6.64% | 4 |
|
|
2025
Q1 | $92M | Buy |
4,675,000
+470,000
| +11% | +$9.25M | 6.78% | 3 |
|
|
2024
Q4 | $94.6M | Buy |
4,205,000
+105,000
| +3% | +$2.36M | 6.93% | 5 |
|
|
2024
Q3 | $105M | Buy |
4,100,000
+126,755
| +3% | +$3.24M | 6.54% | 5 |
|
|
2024
Q2 | $92.9M | Hold |
3,973,245
| – | – | 6.34% | 5 |
|
|
2024
Q1 | $69.9M | Buy |
3,973,245
+1,071,429
| +37% | +$18.8M | 4.67% | 6 |
|
|
2023
Q4 | $40.2M | Hold |
2,901,816
| – | – | 3.51% | 12 |
|
|
2023
Q3 | $39.6M | Buy |
2,901,816
+553,544
| +24% | +$7.56M | 4.63% | 8 |
|
|
2023
Q2 | $47.9M | Buy |
2,348,272
+616,907
| +36% | +$12.6M | 5.39% | 10 |
|
|
2023
Q1 | $37.9M | Buy |
1,731,365
+1,107,666
| +178% | +$24.3M | 5.77% | 7 |
|
|
2022
Q4 | $10.2M | Buy |
+623,699
| New | +$10.2M | 1.54% | 23 |
|